SAN DIEGO, Oct. 26, 2022 - Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T therapies currently being utilized in the treatment of cancers.

CAR-T cells are an immune cellular therapy currently used to treat several leukemias and lymphomas. CAR-T have revolutionized the treatment of these cancers because they utilize the patient's own T cells to kill their own tumor. According to an industry report, "Overall, the global CAR-T cell market for all indications was worth $1.7 billion in 2021 and is forecast to reach $2.4 billion by the end of 2022. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. This makes CAR-T cells one of the fastest growing and potentially profitable therapeutic areas in oncology[1]."

In CAR-T therapy the patient has some of their lymphocytes removed from their body and their T cells are modified in the laboratory. The modification that is made, called a chimeric antigen receptor (CAR) puts a "tag" on the T cell that is specific for the tumor. These modified T cells are expanded into the millions and then infused into the patient. The modified T cells are then capable of homing in on the tumor making the cells more effective at killing the tumor. The results of CAR-T therapy have been spectacular in blood cancer however their use in solid tumors has been stymied because solid tumors are different from blood cancers.

Solid tumors are surrounded by what is called a tumor microenvironment. This microenvironment contains molecules and cells which can turn off the T cells and prevent them from attacking and killing the tumor. In addition, T cells' ability to kill can fade, a phenomenon often referred to as exhaustion. Regen possesses patent pending proprietary intellectual property which may address these issues of both tumor microenvironment as well as cell exhaustion thus allowing CAR-T to act as an effective therapy for solid tumors as well as blood cancers. .

In a future press release, the Company will describe its proprietary CAR-T drug, DuraCAR.

[1] There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma - Pharmaceutical Technology (pharmaceutical-technology.com)

About Regen BioPharma Inc.:

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com

Follow us on Twitter for future updates: https://twitter.com/TheRegenBio

SOURCE Regen BioPharma Inc.